Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9878252 | 1.00 | CES2 (0.47) | CES2CES1CYP1A2CYP2C19RAB9A | |
| SCHEMBL5216994 | 0.90 | CES2 (0.50) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL5216998 | 0.90 | CES2 (0.50) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL9878253 | 0.85 | CES2 (0.58) | CES2CES1CYP1A2CYP2C19RAB9A | |
| SCHEMBL2830742 | 0.85 | CES2 (0.61) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL2830740 | 0.85 | CES2 (0.61) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL1939156 | 0.85 | CES2 (0.61) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL9878258 | 0.85 | CES2 (0.58) | CES2CES1CYP1A2CYP2C19RAB9A | |
| SCHEMBL12560996 | 0.85 | CES2 (0.61) | CES2CES1RAB9AKMT2AMEN1 | |
| SCHEMBL1939154 | 0.85 | CES2 (0.61) | CES2CES1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-4988725-A | Cardiovascular disorders, antiarrhythmia agents | STERLING DRUG INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0388690-A1 | Azole-1-alkanamides as antiarrhytmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0388654-A2 | Azole-1-alkanamides as antiarrhythmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4916150-A | 1H-pyrazole-1-alkanamines antiarrhythmic compositions and use | STERLING DRUG INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4898880-A | N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use | STERLING DRUG INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4870095-A | 1H-pyrazole-1-alkanamides, antiarrhythmic compositions and use | STERLING DRUG, INC. (US) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | CES2 881/4885CES1 84/4885CYP1A2 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.